Automated Author ProfileHeneka, Michael
Heneka, Michael
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 2.6 (sum of 4 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Secondary only controls for western blot(A) Microglia were primed with 100ng/ml LPS for 3 h, incubated with 1μM CRID3 or 100nM NP3-361 for 30 min and 5μM Aβ for 24 h. The lysates or (B) supernatants were prepared for immunoblot, and incubated with secondary only antibodies: goat anti-mouse 800 (used for NLRP3), goat anti-rabbit 680 (used for IL-1β) and goat anti-rat 680 (used for caspase-1). (C) The cortex of 4-, 6- and 12-month-old wild-type, APP/PS1, NLRP3-/- and APP/PS1.NLRP3-/- mice was prepared for immunoblot, and probed with secondary antibodies only. (D) Immunoblot analysis of secondary only controls from the cortex of patients with AD and non-demented, age-matched controls.
Authors
- McManus, Róisín M. ;
- Komes, Max P. ;
- Griep, Angelika ;
- Santarelli, Francesco ;
- Schwartz, Stephanie ;
- Perea, Juan Ramon ;
- Schlachetzki, Johannes C.M. ;
- Bouvier, David S. ;
- Khalil, Michelle-Amirah ;
- Lauterbach, Mario A. ;
- Heinemann, Lea ;
- Schlüter, Titus ;
- Shaban Pour, Mehran ;
- Lovotti, Marta ;
- Stahl, Rainer ;
- Duthie, Fraser ;
- Rodríguez-Alcázar, Juan F. ;
- Schmidt, Susanne V. ;
- Spitzer, Jasper ;
- Noori, Peri ;
- Maillo, Alberto ;
- Boettcher, Andreas ;
- Herron, Brian ;
- McConville, John ;
- Gomez-Cabrero, David ;
- tegner, jesper ;
- Glass, Christopher K. ;
- Hiller, Karsten ;
- Latz, Eicke ;
- Heneka, Michael
Secondary only controls for western blot(A) Microglia were primed with 100ng/ml LPS for 3 h, incubated with 1μM CRID3 or 100nM NP3-361 for 30 min and 5μM Aβ for 24 h. The lysates or (B) supernatants were prepared for immunoblot, and incubated with secondary only antibodies: goat anti-mouse 800 (used for NLRP3), goat anti-rabbit 680 (used for IL-1β) and goat anti-rat 680 (used for caspase-1). (C) The cortex of 4-, 6- and 12-month-old wild-type, APP/PS1, NLRP3-/- and APP/PS1.NLRP3-/- mice was prepared for immunoblot, and probed with secondary antibodies only. (D) Immunoblot analysis of secondary only controls from the cortex of patients with AD and non-demented, age-matched controls.
Authors
- McManus, Róisín M. ;
- Komes, Max P. ;
- Griep, Angelika ;
- Santarelli, Francesco ;
- Schwartz, Stephanie ;
- Perea, Juan Ramon ;
- Schlachetzki, Johannes C.M. ;
- Bouvier, David S. ;
- Khalil, Michelle-Amirah ;
- Lauterbach, Mario A. ;
- Heinemann, Lea ;
- Schlüter, Titus ;
- Shaban Pour, Mehran ;
- Lovotti, Marta ;
- Stahl, Rainer ;
- Duthie, Fraser ;
- Rodríguez-Alcázar, Juan F. ;
- Schmidt, Susanne V. ;
- Spitzer, Jasper ;
- Noori, Peri ;
- Maillo, Alberto ;
- Boettcher, Andreas ;
- Herron, Brian ;
- McConville, John ;
- Gomez-Cabrero, David ;
- tegner, jesper ;
- Glass, Christopher K. ;
- Hiller, Karsten ;
- Latz, Eicke ;
- Heneka, Michael
Table S1. Differentially expressed mRNAs due to alcohol treatment “Alc-DEs”. Shading indicates mRNA levels were confirmed by qPCR. Table S2 Differentially expressed mRNAs due to TII treatment “TII-DEs”. Table S3 Differentially expressed mRNAs due to alcohol and TII treatment “AlcTII-DEs”. Table S4 Treatment-group overlap of differentially expressed mRNAs. Grey, involved in immune effector responses; Blue, mitochondrial ribosomal subunit; Orange, nuclear ribosomal subunit. Table S5 KEGG pathways identified in treatment groups. Table S6 FPKM (fragments per kilobase of transcript per million fragments mapped). (ZIP 3000 kb)
Authors
- Kalinin, Sergey ;
- González-Prieto, Marta ;
- Scheiblich, Hannah ;
- Lisi, Lucia ;
- Handojo Kusumo ;
- Heneka, Michael ;
- Madrigal, Jose ;
- Pandey, Subhash ;
- Feinstein, Douglas
Table S1. Differentially expressed mRNAs due to alcohol treatment “Alc-DEs”. Shading indicates mRNA levels were confirmed by qPCR. Table S2 Differentially expressed mRNAs due to TII treatment “TII-DEs”. Table S3 Differentially expressed mRNAs due to alcohol and TII treatment “AlcTII-DEs”. Table S4 Treatment-group overlap of differentially expressed mRNAs. Grey, involved in immune effector responses; Blue, mitochondrial ribosomal subunit; Orange, nuclear ribosomal subunit. Table S5 KEGG pathways identified in treatment groups. Table S6 FPKM (fragments per kilobase of transcript per million fragments mapped). (ZIP 3000 kb)
Authors
- Kalinin, Sergey ;
- González-Prieto, Marta ;
- Scheiblich, Hannah ;
- Lisi, Lucia ;
- Handojo Kusumo ;
- Heneka, Michael ;
- Madrigal, Jose ;
- Pandey, Subhash ;
- Feinstein, Douglas